Mycophenolate Mofetil NDC 72603-751

NDC codes

FDA NDC Directory

Product NDC (as listed)72603-751Labeler and product segments. Claims need a package NDC.

Product NDC at billing width72603-0751Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
72603-751-01	72603075101	1 BOTTLE in 1 CARTON (72603-751-01) / 225 mL in 1 BOTTLEMarketed from Mar 1, 2026

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Mycophenolate Mofetil
Generic name (nonproprietary): mycophenolate mofetil
Active ingredients: Mycophenolate mofetil — 200 mg/mL
Dosage form: Powder, For suspension
Route: Oral
Labeler: NorthStar Rx LLC
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 218227
Marketing start: Mar 1, 2026
Listing expires: Dec 31, 2027
Identifiers: Product ID 72603-751_127eabe2-8386-452a-ad6b-d879e1f2c099SPL ID 127eabe2-8386-452a-ad6b-d879e1f2c099SPL set ID 127eabe2-8386-452a-ad6b-d879e1f2c099RxCUI 311880UNII 9242ECW6R0UPC 0372603751017
Pharmacologic class: Antimetabolite Immunosuppressant

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N472603075101 followed by a unit qualifier and the quantity

Package 72603-0751-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jan 8, 2026. This label includes a boxed warning.

Indications (excerpt from the label)

Mycophenolate mofetil for oral suspension (MMF) is indicated for the prophylaxis of organ rejection, in adult and pediatric recipients 3 months of age and older of allogeneic kidney [see Clinical Studies (14.1) ], heart [see Clinical Studies (14.2) ] or liver transplants [see Clinical Studies (14.3) ] , in combination with other immunosuppressants. Mycophenolate mofetil is an antimetabolite immunosuppressant indicated for the prophylaxis of organ rejection in adult and pediatric recipients 3 months of age and older of allogeneic kidney, heart or liver transplants, in combination with other immunosuppressants. ( 1 )

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 218227

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 218227
Product	Strength	Form · route	Labeler	Product NDC
Mycophenolate Mofetil	Mycophenolate mofetil 200 mg/mL	Powder, For suspensionOral	Aurobindo Pharma Limited	59651-646